Teva forecasts 'tenfold' growth for new launch Austedo. Why don't analysts agree?

Riding high on the launch of Huntington's disease and tardive dyskinesia (TD) med Austedo, Teva figures the med can top $2 billion, CEO Kare Schultz said, highlighting a bright spot in a decidedly gray picture at the drugmaker. But analysts aren't so sure Austedo can pull it off.